Patents aren’t an obstacle to vaccine delivery – those are from other causes
Adam Mossoff and Amesh Adalja, 2022 – *professor of law at George Mason. **clinical assistant professor at the University of Pittsburgh School of Medicine “Patents as a Driver of the Unprecedented Biomedical Response to COVID-19” INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 9/21, https://journals.sagepub.com/doi/10.1177/00469580221124819 //DH
Admittedly, the delivery of vaccine doses has not been as widespread in developing countries as it has been in developed countries; as of June 2022, approximately 4.8 billion doses were delivered to patients in lower-income and lower-middle-income countries out of the 14 billion total doses delivered worldwide.2 But this has nothing to do with patents or any other IP rights. The causes are myriad, ranging from regulatory and trade barriers, lack of distribution infrastructure in the developing world, to vaccine hesitancy in some populations.